Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CRIS, Curis (formerly CBMI) -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (357)	1/30/2001 12:31:56 PM
From: Jim Oravetz	Read Replies (1) \| Respond to of 668

CAMBRIDGE, Mass. -- Shares of Curis Inc. were off 48.1%, or $6.25, to $6.75 late Tuesday morning, following news that the company's OP-1 implant for fractures of the tibia received a "Not-Approvable" letter from the Food and Drug Administration. In a press release Tuesday, the medical technology company said its licensee for OP-1, Stryker Corp. (SYK), received the FDA letter, which cited statistical reporting problems in the Pre-Market Approval application. Stryker reported the FDA letter Jan. 29, but did not mention Curis as the licensee. The FDA recommended that Stryker conduct a new study, and the company intends to continue to pursue approval and hopes to meet with the FDA shortly, Curis said. New York Stock Exchange-listed shares of Stryker traded recently at $46.36, down 56 cents, or 1.3%, on composite volume of 641,500 shares. Average daily volume is 900,907.